These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 28762205)

  • 41. Recent developments in adeno-associated virus vector technology.
    Büning H; Perabo L; Coutelle O; Quadt-Humme S; Hallek M
    J Gene Med; 2008 Jul; 10(7):717-33. PubMed ID: 18452237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Breaking the sound barrier: Towards next-generation AAV vectors for gene therapy of hearing disorders.
    Fakhiri J; Landegger LD; Grimm D
    Hear Res; 2022 Jan; 413():108092. PubMed ID: 33268240
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimization of design and production strategies for novel adeno-associated viral display peptide libraries.
    Körbelin J; Hunger A; Alawi M; Sieber T; Binder M; Trepel M
    Gene Ther; 2017 Aug; 24(8):470-481. PubMed ID: 28622288
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Next-Generation Gene Therapy for Parkinson's Disease Using Engineered Viral Vectors.
    Björklund T; Davidsson M
    J Parkinsons Dis; 2021; 11(s2):S209-S217. PubMed ID: 34366370
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In Vivo Selection of a Computationally Designed SCHEMA AAV Library Yields a Novel Variant for Infection of Adult Neural Stem Cells in the SVZ.
    Ojala DS; Sun S; Santiago-Ortiz JL; Shapiro MG; Romero PA; Schaffer DV
    Mol Ther; 2018 Jan; 26(1):304-319. PubMed ID: 28988711
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chimeric AAV Cap sequences alter gene transduction.
    Ward P; Walsh CE
    Virology; 2009 Apr; 386(2):237-48. PubMed ID: 19232422
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AAV capsid design: A Goldilocks challenge.
    Zolotukhin S; Vandenberghe LH
    Trends Mol Med; 2022 Mar; 28(3):183-193. PubMed ID: 35093287
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pulmonary Targeting of Adeno-associated Viral Vectors by Next-generation Sequencing-guided Screening of Random Capsid Displayed Peptide Libraries.
    Körbelin J; Sieber T; Michelfelder S; Lunding L; Spies E; Hunger A; Alawi M; Rapti K; Indenbirken D; Müller OJ; Pasqualini R; Arap W; Kleinschmidt JA; Trepel M
    Mol Ther; 2016 Jun; 24(6):1050-1061. PubMed ID: 27018516
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking.
    Lux K; Goerlitz N; Schlemminger S; Perabo L; Goldnau D; Endell J; Leike K; Kofler DM; Finke S; Hallek M; Büning H
    J Virol; 2005 Sep; 79(18):11776-87. PubMed ID: 16140755
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Engineering AAV receptor footprints for gene therapy.
    Madigan VJ; Asokan A
    Curr Opin Virol; 2016 Jun; 18():89-96. PubMed ID: 27262111
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Direct Liquid Chromatography/Mass Spectrometry Analysis for Complete Characterization of Recombinant Adeno-Associated Virus Capsid Proteins.
    Jin X; Liu L; Nass S; O'Riordan C; Pastor E; Zhang XK
    Hum Gene Ther Methods; 2017 Oct; 28(5):255-267. PubMed ID: 28627251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy.
    Naso MF; Tomkowicz B; Perry WL; Strohl WR
    BioDrugs; 2017 Aug; 31(4):317-334. PubMed ID: 28669112
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthetically Engineered Adeno-Associated Virus for Efficient, Safe, and Versatile Gene Therapy Applications.
    Lugin ML; Lee RT; Kwon YJ
    ACS Nano; 2020 Nov; 14(11):14262-14283. PubMed ID: 33073995
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adeno-associated Virus as a Mammalian DNA Vector.
    Salganik M; Hirsch ML; Samulski RJ
    Microbiol Spectr; 2015 Aug; 3(4):. PubMed ID: 26350320
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Receptor targeting of adeno-associated virus vectors.
    Büning H; Ried MU; Perabo L; Gerner FM; Huttner NA; Enssle J; Hallek M
    Gene Ther; 2003 Jul; 10(14):1142-51. PubMed ID: 12833123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Isolating Natural Adeno-Associated Viruses from Primate Tissues with a High-Fidelity Polymerase.
    Wang Q; Nambiar K; Wilson JM
    Hum Gene Ther; 2021 Dec; 32(23-24):1439-1449. PubMed ID: 34448594
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cryo-electron Microscopy Reconstruction and Stability Studies of the Wild Type and the R432A Variant of Adeno-associated Virus Type 2 Reveal that Capsid Structural Stability Is a Major Factor in Genome Packaging.
    Drouin LM; Lins B; Janssen M; Bennett A; Chipman P; McKenna R; Chen W; Muzyczka N; Cardone G; Baker TS; Agbandje-McKenna M
    J Virol; 2016 Oct; 90(19):8542-51. PubMed ID: 27440903
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency.
    Shen X; Storm T; Kay MA
    Mol Ther; 2007 Nov; 15(11):1955-62. PubMed ID: 17726459
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High capsid-genome correlation facilitates creation of AAV libraries for directed evolution.
    Nonnenmacher M; van Bakel H; Hajjar RJ; Weber T
    Mol Ther; 2015 Apr; 23(4):675-82. PubMed ID: 25586687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generation of efficient human blood progenitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells.
    Sellner L; Stiefelhagen M; Kleinschmidt JA; Laufs S; Wenz F; Fruehauf S; Zeller WJ; Veldwijk MR
    Exp Hematol; 2008 Aug; 36(8):957-64. PubMed ID: 18495326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.